Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2008

ImmunoVaccine Technologies Receives Funding to Further Cancer and Infectious Disease Vaccine Development

  • ImmunoVaccine Technologies (IVT) will obtain C$3 million from the Atlantic Canada Opportunities Agency (ACOA) to develop new potent immune enhancement systems. The funding was received under the Atlantic Innovation Fund. The work will be a part of a C$6 million project.

    “This funding will enable us, over the next three years, to create novel vaccines for the treatment of cancer and infectious diseases,” comments Brian Lowe, vp. IVT also says that the financing will further its research collaborations and commercialization opportunities with pharmaceutical companies worldwide.

    IVT developed a vaccine-enhancement technology called the VacciMax®. It comprises a mixture of liposomes and adjuvants. The platform is able to stimulate an earlier, more powerful, long-lasting immune response that could provide a new way to treat a wide range of diseases, according to the firm.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »